Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO IBD -study.

Bernd BokemeyerSandra Plachta-DanielzikRomina di GiuseppePhilipp EfkenWolfgang MohlThomas KrauseMartin HoffstadtRobert EhehaltLeo TrentmannAxel SchweitzerPetra JessenPetra HartmannStefan Schreiber

Published in: Alimentary pharmacology & therapeutics (2023)

After two years of treatment, vedolizumab resulted in higher remission rates than anti-TNF agents.

Keyphrases

ulcerative colitis
rheumatoid arthritis
randomized controlled trial
systematic review
disease activity
systemic lupus erythematosus
combination therapy
replacement therapy
smoking cessation
patients with inflammatory bowel disease